Establishment Labs (NASDAQ:ESTA) Director Quiros Juan Jose Chacon Sells 2,180 Shares

Establishment Labs Holdings Inc. (NASDAQ:ESTA) Director Quiros Juan Jose Chacon sold 2,180 shares of Establishment Labs stock in a transaction dated Monday, April 27th. The stock was sold at an average price of $66.26, for a total transaction of $144,446.80. Following the completion of the transaction, the director directly owned 1,107,504 shares of the company’s stock, valued at $73,383,215.04. This trade represents a 0.20% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Quiros Juan Jose Chacon also recently made the following trade(s):

• On Friday, April 24th, Quiros Juan Jose Chacon sold 30,178 shares of Establishment Labs stock. The stock was sold at an average price of $65.78, for a total transaction of $1,985,108.84.
• On Thursday, April 23rd, Quiros Juan Jose Chacon sold 42,642 shares of Establishment Labs stock. The stock was sold at an average price of $65.43, for a total transaction of $2,790,066.06.
• On Tuesday, April 14th, Quiros Juan Jose Chacon sold 37,500 shares of Establishment Labs stock. The stock was sold at an average price of $65.23, for a total transaction of $2,446,125.00.
• On Wednesday, March 25th, Quiros Juan Jose Chacon sold 3,575 shares of Establishment Labs stock. The stock was sold at an average price of $60.08, for a total transaction of $214,786.00.
• On Monday, March 23rd, Quiros Juan Jose Chacon sold 33,925 shares of Establishment Labs stock. The stock was sold at an average price of $60.39, for a total transaction of $2,048,730.75.

Establishment Labs Stock Performance

Shares of ESTA stock opened at $65.47 on Tuesday. The company has a 50 day moving average price of $66.15 and a 200-day moving average price of $65.53. Establishment Labs Holdings Inc. has a 52 week low of $28.89 and a 52 week high of $83.31. The firm has a market capitalization of $1.92 billion, a PE ratio of -37.63 and a beta of 1.08. The company has a quick ratio of 2.00, a current ratio of 3.04 and a debt-to-equity ratio of 10.51.

Establishment Labs (NASDAQ:ESTA) last announced its quarterly earnings results on Tuesday, February 24th. The company reported ($0.09) EPS for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.13. Establishment Labs had a negative net margin of 24.19% and a negative return on equity of 201.79%. The firm had revenue of $64.62 million during the quarter, compared to analyst estimates of $63.80 million. During the same period in the previous year, the business posted ($1.19) earnings per share. The business’s revenue for the quarter was up 45.2% on a year-over-year basis. As a group, equities research analysts expect that Establishment Labs Holdings Inc. will post -0.86 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages have recently commented on ESTA. Stephens lifted their price target on shares of Establishment Labs from $85.00 to $90.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 25th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Establishment Labs in a research note on Friday, March 27th. Canaccord Genuity Group lifted their price target on shares of Establishment Labs from $85.00 to $90.00 and gave the stock a “buy” rating in a research note on Thursday, February 26th. Mizuho boosted their target price on shares of Establishment Labs from $90.00 to $100.00 and gave the company an “outperform” rating in a research report on Wednesday, February 25th. Finally, Needham & Company LLC boosted their target price on shares of Establishment Labs from $84.00 to $86.00 and gave the company a “buy” rating in a research report on Tuesday, February 24th. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $86.86.

Institutional Trading of Establishment Labs

Large investors have recently added to or reduced their stakes in the business. Simplify Asset Management Inc. bought a new stake in Establishment Labs during the third quarter valued at approximately $1,555,000. Tejara Capital Ltd grew its position in Establishment Labs by 31.2% during the third quarter. Tejara Capital Ltd now owns 102,494 shares of the company’s stock valued at $4,201,000 after buying an additional 24,386 shares during the period. Woodson Capital Management LP grew its position in Establishment Labs by 113.3% during the third quarter. Woodson Capital Management LP now owns 480,000 shares of the company’s stock valued at $19,675,000 after buying an additional 255,000 shares during the period. William Blair Investment Management LLC grew its position in Establishment Labs by 17.6% during the third quarter. William Blair Investment Management LLC now owns 1,017,543 shares of the company’s stock valued at $41,709,000 after buying an additional 152,299 shares during the period. Finally, Assenagon Asset Management S.A. grew its position in Establishment Labs by 59.4% during the fourth quarter. Assenagon Asset Management S.A. now owns 115,876 shares of the company’s stock valued at $8,445,000 after buying an additional 43,164 shares during the period. 72.91% of the stock is currently owned by institutional investors.

Establishment Labs Company Profile

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.